Bradley L. Radoff and Michael Torok Reach Agreement with Atea Pharmaceuticals for Board Changes and Share Repurchase Program

StreetInsider and other media sources reported that Olshan clients Bradley L. Radoff and Michael Torok reached an agreement with Atea Pharmaceuticals (Nasdaq: AVIR) pursuant to which Howard H. Berman, Ph.D. will be appointed to the company’s board of directors. In connection with the agreement, Atea also announced the authorization of a $25 million share repurchase program and that the company’s lead director will not stand for re-election when his term expires. Vice Chair of Olshan’s Shareholder Activism Practice Group Ryan Nebel, Rebecca Van Derlaske and Joseph Ferrone represented Bradley L. Radoff and Michael Torok in connection with their investment in Atea Pharmaceuticals.